Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Traitement immunomodulateur de la maladie pulmonaire interstitielle associée aux variants géniques liés au surfactant (TIPS)

17 septembre 2026 mis à jour par: Assistance Publique - Hôpitaux de Paris

Traitement immunomodulateur de la pneumopathie interstitielle associée aux variants des gènes liés au surfactant

Scientific justification : Variants in surfactant-related genes (SRG) explain approximately 6% of familial pulmonary fibrosis (FPF).

The pathophysiology is unknown and seems to involve endoplasmic reticulum stress in type 2 alveolar epithelial cells.

Variable improvement in the prognosis of childhood and adult interstitial lung disease (ILD) associated with a variant of a SRG, initially reported to be lethal within months of diagnosis, has been observed since the consensual use of prednisone, azithromycin and hydroxychloroquine targeting endoplasmic reticulum stress, without demonstration of the efficacy of any of these treatments alone or in combination.

The investigators hypothesize that a treatment combining prednisone, azithromycin and hydroxychloroquine is safe and could improve the prognosis of adult patients with ILD associated with SRG variant.

Main objective and primary endpoint : Main objective:

Evaluate the efficacy of triple immunomodulatory therapy (prednisone, azithromycin and hydroxychloroquine) for 12 months in patients with ILD associated with a variant of a surfactant-related gene.

Primary endpoint:

Difference in forced vital capacity decline between the 2 groups at one year.

Secondary objectives and endpoints : Secondary objectives:

  1. tolerance of the triple therapy,
  2. correlation between the respiratory, radiological and clinical functional response,
  3. quality of life of the patients,
  4. overall survival, transplant-free survival, exacerbation free-survival, hospitalization-free survival

Secondary endpoints:

  1. Clinical and biological tolerance (occurrence of an adverse effect during treatment), ECG (at 3, 6, 9, 12 months after randomization) (only HCQ or AZI patients) and ophthalmological (at one year after randomization)
  2. Thoracic CT scan and PFT at 6 months and one year after randomization
  3. Quality of life questionnaire (EORTC QLQ-C30, v3.0) at 3 months, 6 months, 9 months and one year after randomization,
  4. Collection of vital status, lung transplantation, hospitalization for pulmonary and non-pulmonary causes and episodes of exacerbation at each visit until the end of follow-up 12 months after randomization.

Design of the study : Multicenter, randomized, controlled, two-arm, parallel, open-label superiority study comparing triple immunomodulatory therapy (prednisone, azithromycin, and hydroxychloroquine) to standard of care

Category : Category 2

Population of study participants: Patients aged over 18 years with ILD and SRG variant

Number of participants included : 30

Design of the study : Multicenter, randomized, controlled, two-arm, parallel, open-label superiority study comparing triple immunomodulatory therapy (prednisone, azithromycin, and hydroxychloroquine) to standard of care.

Aperçu de l'étude

Type d'étude

Interventionnel

Inscription (Estimé)

30

Phase

  • Phase 2

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Lieux d'étude

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 80 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  1. Age ≥ 18 years and <80 years
  2. Carrier of a variant classified as pathogenic or probably pathogenic or considered as eligible by the genetic multidisciplinary discussion in SFTPA1, SFTPA2, SFTPC, NKX2-1, SFTPB or two variants classified as pathogenic or probably pathogenic or considered as eligible by the genetic multidisciplinary discussion in ABCA3 or SFTPB
  3. ILD whatever the pattern corresponding to a volume > 10% of the total lung on a CT scan of less than 2 years

Exclusion Criteria:

  1. Contraindication to azithromycin and hydroxychloroquine and prednisone (details in section 6.2)
  2. Pregnancy and breastfeeding
  3. Female of childbearing potential* not willing to use reliable contraception from inclusion and during 22 months
  4. Desire to have a child within 22 months
  5. Enrolment to another interventional study (clinical trial on medicinal product, medical device and interventional research involving human participants not concerning health product)
  6. Subject deprived of their liberty or subject that may have insufficient power, intelligence, education, resources, strength, or other needed attributes to protect their own interests; or unable to explicitly give consent.
  7. No affiliation to any health insurance system
  8. Refusal to participate to the study

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Prednisone 10 mg/day -Hydroxychloroquine 400 mg/day - Azithromycin 250mg*3

The experimental treatment will be the combination of:

  • Prednisone 10 mg/day (1 tablet/day)
  • Hydroxychloroquine 400 mg/day (2 tablets/day)
  • Azithromycin 250 mg x3/week (3 tablets/week) Route of administration: oral route Duration of treatment: 12 months Market authorization: yes Use in their market authorization indication: no

Route of administration: oral route Duration of treatment: 12 months Market authorization: yes Use in their market authorization indication: no

Route of administration: oral route Duration of treatment: 12 months Market authorization: yes Use in their market authorization indication: no

Route of administration: oral route Duration of treatment: 12 months Market authorization: yes Use in their market authorization indication: no

Comparateur actif: Standard of care

Standard of care: any symptomatic treatment to interstitial lung disease. No other experimental or off-label treatment (such as ivacaftor) will be allowed during the study.

Standard of care: any symptomatic treatment to interstitial lung disease. No other experimental or off-label treatment (such as ivacaftor) will be allowed during the study.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Difference in forced vital capacity decline between the 2 groups at one year.
Délai: 12 Months

Evaluate the efficacy of triple immunomodulatory therapy (prednisone, azithromycin and hydroxychloroquine) for 12 months in patients with ILD associated with a variant of a surfactant-related gene.

12 Months

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
tolerance of the triple therapy
Délai: 12 months

Clinical and biological tolerance (occurrence of an adverse effect during treatment), ECG (including QTc prolongation) (at 3, 6, 9, 12 months after randomization) (only HCQ or AZI patients) and ophthalmological (at 6 months and 12 months after randomization)

12 months
correlation between the respiratory, radiological and clinical functional response,
Délai: 12 months

Thoracic CT scan (progression criteria [99]) and PFT (Pulmonary function tests) at one year after randomization

12 months
Quality of life of the patients
Délai: 12 months

Quality of life questionnaire (SF-36, scale from 0 to 100, where 0 represents the poorest health and 100 represents the best possible health) (EORTC QLQ-C30, v3.0 : a validated patient-reported questionnaire for assessing quality of life in cancer patients.) at one year after randomization,

12 months
tolerance of the triple therapy
Délai: 6 months

Clinical and biological tolerance (occurrence of an adverse effect during treatment), ECG (including QTc prolongation) at 6, months after randomization (only HCQ or AZI patients) and ophthalmological (at one year after randomization)

6 months
tolerance of the triple therapy
Délai: 3 months

Clinical and biological tolerance (occurrence of an adverse effect during treatment), ECG (including QTc prolongation) at 3 months after randomization (only HCQ or AZI patients) and ophthalmological (at one year after randomization)

3 months
correlation between the respiratory, radiological and clinical functional response,
Délai: 6 months

Thoracic CT scan (progression criteria [99]) and PFT (Pulmonary function tests) at 6 months after randomization

6 months
Quality of life of the patients
Délai: 9 months

Quality of life questionnaire (SF-36,scale from 0 to 100, where 0 represents the poorest health and 100 represents the best possible health) (EORTC QLQ-C30, v3.0 : a validated patient-reported questionnaire for assessing quality of life in cancer patients.) at 9 months after randomization,

9 months
Quality of life of the patients
Délai: 6 months

Quality of life questionnaire (SF-36 scale from 0 to 100, where 0 represents the poorest health and 100 represents the best possible health) (EORTC QLQ-C30, v3.0 :a validated patient-reported questionnaire for assessing quality of life in cancer patients. ) at 6 months after randomization,

6 months
Quality of life of the patients
Délai: 3 months

Quality of life questionnaire (SF-36, scale from 0 to 100, where 0 represents the poorest health and 100 represents the best possible health) (EORTC QLQ-C30, v3.0 :a validated patient-reported questionnaire for assessing quality of life in cancer patients ) at 3 months after randomization,

3 months
Overall survival
Délai: 12 months

Collection of vital status, lung transplantation, hospitalization for pulmonary and non-pulmonary causes and episodes of exacerbation at each visit until the end of follow-up 12 months after randomization

12 months
Transplant-free survival
Délai: 12 months

Collection of vital status, lung transplantation, hospitalization for pulmonary and non-pulmonary causes and episodes of exacerbation at each visit until the end of follow-up 12 months after randomization

12 months
Exacerbation free-survival
Délai: 12 months

Collection of vital status, lung transplantation, hospitalization for pulmonary and non-pulmonary causes and episodes of exacerbation at each visit until the end of follow-up 12 months after randomization

12 months
Hospitalization-free survival
Délai: 12 months

Collection of vital status, lung transplantation, hospitalization for pulmonary and non-pulmonary causes and episodes of exacerbation at each visit until the end of follow-up 12 months after randomization

12 months
tolerance of the triple therapy
Délai: 9 months

Clinical and biological tolerance (occurrence of an adverse effect during treatment),

9 months
tolerance of the triple therapy
Délai: 12 months

ECG (including QTc prolongation) at 12 months after randomization (only HCQ or AZI patients)

12 months
tolerance of the triple therapy
Délai: 12 months

Ophthalmological (at one year after randomization)

12 months
tolerance of the triple therapy
Délai: 9 months

ECG (including QTc prolongation) at , 9 months after randomization (only HCQ or AZI patients)

9 months
tolerance of the triple therapy
Délai: 6 months

ECG (including QTc prolongation) at 6 months after randomization (only HCQ or AZI patients)

6 months
tolerance of the triple therapy
Délai: 3 months

ECG (including QTc prolongation) at 3 months after randomization (only HCQ or AZI patients)

3 months
Overall survival
Délai: 9 months

Collection of vital status, lung transplantation, hospitalization for pulmonary and non-pulmonary causes and episodes of exacerbation at each visit until the end of follow-up 9 months after randomization

9 months
Overall survival
Délai: 6 months

Collection of vital status, lung transplantation, hospitalization for pulmonary and non-pulmonary causes and episodes of exacerbation at each visit until the end of follow-up 6 months after randomization

6 months
Overall survival
Délai: 3 months

Collection of vital status, lung transplantation, hospitalization for pulmonary and non-pulmonary causes and episodes of exacerbation at each visit until the end of follow-up 3 months after randomization

3 months

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 novembre 2026

Achèvement primaire (Estimé)

1 novembre 2027

Achèvement de l'étude (Estimé)

1 novembre 2027

Dates d'inscription aux études

Première soumission

11 février 2026

Première soumission répondant aux critères de contrôle qualité

27 février 2026

Première publication (Réel)

2 mars 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

22 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

17 septembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner